Synta plans cautious approach to Phase III for its HSP inhibitor
This article was originally published in Scrip
Synta Pharmaceuticals is sufficiently encouraged by interim Phase II data for its heat shock protein inhibitor ganetespib (STA-9090) in non-small cell lung cancer to take the product into a Phase IIb/III trial in this indication next quarter. The promising results are a boon for the company which suffered disappointment with its former lead product elesclomol in melanoma and they will strengthen its hand as it seeks a licensing partner.
You may also be interested in...
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.